A Phase IA/IB, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs BGB 290 (Primary)
- Indications Breast cancer; Cancer; Glioblastoma; Ovarian cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors BeiGene
- 07 Feb 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.
- 07 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 09 Oct 2016 Planned number of patients changed from 30 to 85.